Please download and print the PDF file below:

Richard Amerling, MD

Richard Amerling, MD, is Associate Professor of Clinical Medicine, Albert Einstein College of Medicine, New York, NY, and Director, Outpatient Dialysis and CRRT, Beth Israel Medical Center, New York, NY. He disclosed that he is on the Consultant Presenter Bureau for Amgen, Inc., Ortho Biotech, and Watson Pharma, Inc.

Andrea Easom, MA, MNSc, APN, BC, CNNNP

Andrea Easom, MA, MNSc, APN, BC, CNNNP, is an Instructor, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR. She is President and State Legislative Director of ANNA’s Arkansas Chapter. The author disclosed that she is on the Consultant Presenter Bureau for Amgen, Inc. and Watson Pharma, Inc.

Peter Juergensen, PA-C

Peter Juergensen, PA-C, is a Physician Assistant – Nephrology, Metabolism Associates, Yale University School of Medicine, New Haven, CT. The author has disclosed that he receives grant/research support from Watson Pharma, Inc.

The latest considerations in the management of iron-deficiency anemia in patients on hemodialysis have centered on the updated guidelines and recommendations issued by the National Kidney Foundation, with interest on appropriate hemoglobin and serum ferritin targets. With practices evolving in the anemia environment, it is necessary for nurses to stay informed of new evidence-based data and practical solutions to improve patient outcomes. This underscores the importance of a team approach to managing anemia and balanced therapy with intravenous iron and erythropoiesis-stimulating agents. A symposium held during the 2007 annual meeting of the American Nephrology Nurses’ Association addressed these issues. This article is based on the presentations and discussions from that symposium.